24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
MOZOLIEVA 24MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | MOZOLIEVA 24MG |
|---|---|
| Composition | Plerixafor Injection 24mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
MOZOLIEVA 24MG (Plerixafor Injection 24mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
MOZOLIEVA 24 MG (Plerixafor Injection 24 mg) is a prescription hematology medicine used to help mobilize hematopoietic stem cells from the bone marrow into the bloodstream for collection and subsequent autologous stem cell transplantation. It contains Plerixafor 24 mg, a selective CXCR4 chemokine receptor antagonist that plays a crucial role in stem cell mobilization for patients undergoing treatment for certain blood cancers and hematological disorders.
Stem cell transplantation is an important treatment option for patients with conditions such as Multiple Myeloma and Non-Hodgkin Lymphoma. Before transplantation can take place, a sufficient number of healthy stem cells must be collected from the patient's bloodstream. In some patients, collecting an adequate number of stem cells can be challenging. MOZOLIEVA 24 MG helps overcome this challenge by increasing the release of stem cells from the bone marrow into the circulation, making collection more efficient.
Plerixafor works by blocking the interaction between the CXCR4 receptor and its natural ligand, stromal cell-derived factor-1 (SDF-1). This disruption allows stem cells to move from the bone marrow into the bloodstream, where they can be collected through a process called apheresis.
MOZOLIEVA 24 MG is commonly used for:
• Stem Cell Mobilization
• Autologous Stem Cell Transplantation
• Multiple Myeloma Treatment Programs
• Non-Hodgkin Lymphoma Treatment Programs
• Hematopoietic Stem Cell Collection
• Bone Marrow Supportive Care
• Advanced Hematology Treatment Protocols
• Specialized Oncology and Transplant Centers
The medicine is generally administered in combination with Granulocyte Colony-Stimulating Factor (G-CSF) to enhance stem cell mobilization and improve collection success rates.
Manufactured under strict pharmaceutical quality standards, MOZOLIEVA 24 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals experienced in hematology, oncology, and stem cell transplantation procedures.
Patients receiving Plerixafor therapy may require regular blood count monitoring, stem cell collection assessments, and medical supervision to ensure effective mobilization and optimal transplant preparation.
Due to its effectiveness in improving stem cell collection, MOZOLIEVA 24 MG has become an important supportive medicine in modern hematology and transplant medicine.
MOZOLIEVA 24 MG (Plerixafor Injection 24 mg) is primarily used to assist in stem cell mobilization and collection.
The medicine helps release stem cells from the bone marrow into the bloodstream for collection.
Doctors may prescribe Plerixafor to facilitate stem cell collection in patients with multiple myeloma.
The medicine is commonly used before stem cell transplantation in eligible lymphoma patients.
MOZOLIEVA supports the collection of stem cells needed for transplantation procedures.
The medicine improves the efficiency of stem cell harvesting through apheresis.
Plerixafor is frequently used in advanced transplant and hematology treatment programs.
Plerixafor belongs to a class of medicines known as CXCR4 Receptor Antagonists.
MOZOLIEVA works by:
This mechanism helps healthcare providers collect sufficient stem cells for transplant preparation.
Like all prescription medicines, MOZOLIEVA 24 MG may cause side effects in some patients. Side effects vary depending on individual response and treatment conditions.
Digestive disturbances and loose stools may occur.
Patients may experience mild to moderate nausea after administration.
Weakness and tiredness are commonly reported.
Some individuals may develop mild headaches.
Lightheadedness or dizziness may occur.
Redness, swelling, itching, or discomfort at the injection site may develop.
Mild stomach discomfort or abdominal cramping may occur.
Musculoskeletal discomfort may be experienced during treatment.
Some patients may report temporary sleep disturbances.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of MOZOLIEVA 24 MG (Plerixafor Injection 24 mg) should always be determined by a qualified hematologist or transplant specialist.
Dosage is typically calculated according to the patient's body weight.
Treatment protocols may vary depending on the underlying disease.
The number of stem cells needed influences treatment planning.
Patients with kidney impairment may require dosage adjustments.
Plerixafor is often used alongside growth factor therapy, which may influence treatment schedules.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently using to avoid possible drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is used to mobilize stem cells into the bloodstream for collection before autologous stem cell transplantation.
Plerixafor is a CXCR4 receptor antagonist that helps release stem cells from the bone marrow into the bloodstream.
It is commonly used in patients with multiple myeloma and non-Hodgkin lymphoma undergoing stem cell transplantation.
No, it is a stem cell mobilization medicine used as part of transplant preparation.
It is often administered in combination with Granulocyte Colony-Stimulating Factor (G-CSF) to improve stem cell collection.
Yes, doctors typically monitor blood counts, stem cell levels, and overall treatment response.
No, treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in hematology, oncology, and stem cell transplantation procedures.